From: A pilot study of topiramate dosages for migraine prophylaxis in an Asian population
Time | Baseline | Time 1 | Time 2 | Time 3 |
---|---|---|---|---|
Frequency (days) | ||||
25 mg | 10.2 (5.1) | 7.6 (6.4) | 3.5 (2.2) | 4.1 (1.9) |
50 mg | 6.9 (2.6) | 8.1 (4.2) | 6.5 (4.8) | 6.8 (5.7) |
75 mg | 8.8 (4.4) | 6.2 (5.9) | 5.8 (6.6) | 3.3 (4.4) |
100 mg | 8.0 (2.5) | 8.8 (8.2) | 4.3 (2.4) | 2.3 (1.5) |
p = 0.001* | ||||
Duration (h) | ||||
25 mg | 8.4 (3.8) | 9.2 (5.5) | 10.1 (8.0) | 6.9 (7.7) |
50 mg | 8.8 (8.6) | 6.0 (6.1) | 5.3 (5.3) | 5.9 (5.4) |
75 mg | 5.3 (4.7) | 7.7 (6.3) | 10.9 (2.6) | 12.3 (8.0) |
100 mg | 7.9 (7.1) | 6.4 (8.8) | 7.3 (3.1) | 8.0 (5.7) |
p = 0.82 | ||||
Severity (VAS) | ||||
25 mg | 5.1 (1.2) | 5.1 (1.9) | 5.6 (1.7) | 4.9 (0.8) |
50 mg | 6.3 (1.3) | 6.0 (0.5) | 5.1 (1.3) | 5.8 (1.4) |
75 mg | 5.0 (1.5) | 4.4 (1.4) | 4.0 (1.4) | 4.3 (1.4) |
100 mg | 5.7 (1.2) | 5.8 (1.5) | 4.8 (1.4) | 4.8 (1.4) |
p = 0.75 |